These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23863207)

  • 21. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
    Paikin JS; Manolakos JJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
    Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
    Hosp Pract (1995); 2014 Aug; 42(3):17-25. PubMed ID: 25255403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Ahmad Y; Lip GY
    Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
    Morales-Vidal S; Schneck MJ; Flaster M; Biller J
    Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
    Testa L; Agnifili M; Latini RA; Mattioli R; Lanotte S; De Marco F; Oreglia J; Latib A; Pizzocri S; Laudisa ML; Brambilla N; Bedogni F
    QJM; 2012 Oct; 105(10):949-57. PubMed ID: 22771555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Apixaban (Eliquis) the "ideal" anticoagulant to replace warfarin for stroke prevention in atrial fibrillation?
    Strain J; Templeton K
    S D Med; 2013 Jan; 66(1):20-1. PubMed ID: 23342716
    [No Abstract]   [Full Text] [Related]  

  • 32. Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future.
    Rajappan K
    Heart; 2013 Mar; 99(6):361-2. PubMed ID: 23024007
    [No Abstract]   [Full Text] [Related]  

  • 33. [Novel anticoagulants for stroke prevention in atrial fibrillation].
    Baumhäkel M; Schirmer SH; Böhm M
    Dtsch Med Wochenschr; 2010 Nov; 135(46):2304-8. PubMed ID: 21064013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
    Prescrire Int; 2012 Nov; 21(132):257-60. PubMed ID: 23210252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
    Hammwöhner M; Goette A
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):18-27. PubMed ID: 18594479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The X-VeRT study].
    Colonna P; Troccoli R; Botto GL
    G Ital Cardiol (Rome); 2015 Jun; 16(6):325-8; discussion 328-30. PubMed ID: 26156692
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm.
    Chaudhari D; Bhuriya R; Arora R
    Am J Ther; 2011 Jan; 18(1):e1-e11. PubMed ID: 20460986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.